Anavex Life Sciences Corp (AVXL)

[jimmy667]

Improvement of cognition MAYBE irrelevant for approval of A2-73 or A2-73PLUS.

Did Anavex measure these in the current trial? Yes

Does a company need to 'Cure' Alzheimer's or improve cognition and memory in order to gain approval by the FDA?

NO! Symptomatic improvement above the current SOC or non-inferiority with greater safety profile is all that is necessary.

Did Anavex show some surprising and remarkable symptomatic benefits of A2-73 in the current trial?

LOOK at it!

Why did all the Abeta plaque and Tau tangle trials focus on cognition and memory improvement?

Because although many were successful in removing the plaque or tau they did not improve the lives or symptoms of the patients. Many had bad side effects including the BIIB brain bleed for its drug. So they search really hard to show improvements in cognition or memory.

It will be nice if A2-73 or A2-73Plus show improvement in cognition or memory. But it is not necessary to greatly improve the lives of ALZ sufferers or to make the drug a blockbuster.

Case in point Acadia and its symptomatic improvement drug for Parkinson's and the resulting large increases in Acadia's market cap.

Does the Market understand all this? Apparently not.

Will the Market start to realize this when the trial design is approved by the FDA with symptomatic relief endpoints?

You tell me or wait and see!